JAK1 Inhibitor From Galapagos Headed To Phase III – With Or Without AbbVie
This article was originally published in The Pink Sheet Daily
Executive Summary
Filgotinib posts promising interim Phase IIb results in rheumatoid arthritis; although more results are to come. AbbVie seems likely to opt in later this year on the potential successor to Humira.
You may also be interested in...
After The Anti-TNFs, What’s Next In Autoimmune Disease?
With the threat of biosimilars looming closer, the leaders in autoimmune disease are scrambling to bring novel drugs to market and extend their dominance beyond the anti-TNF class. But toppling the anti-TNFs’ reign won’t be easy, especially if cheaper biosimilar copies reach the market.
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.